美国 · SEC FORM 4
VERTEX PHARMACEUTICALS INC / MA
VRTX · Nasdaq · CIK 0000875320 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
28 同一窗口内观察到的 Form 4 交易行
14 sales · 14 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 9 additional owner(s) remain in Form 4 申报证据.
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-08-06 · Kewalramani Reshma.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 4,503,200
- 上期报告
- 4,716,867
- 日均成交量
- 1,063,142
- 回补天数
- 4.2
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-08-06 | SACHS BRUCE I | 买入 (P) | Common Stock | 5,000 | USD 389.68 | USD 1,948,416 | SEC 申报 ↗ |
| 2025-08-06 | Kewalramani Reshma | 买入 (P) | Common Stock | 10,000 | USD 389.58 | USD 3,895,768 | SEC 申报 ↗ |
| 2021-08-19 | Kewalramani Reshma | 买入 (P) | Common Stock | 10,000 | USD 195.65 | USD 1,956,492 | SEC 申报 ↗ |
| 2021-08-02 | SACHS BRUCE I | 买入 (P) | Common Stock | 15,000 | USD 197.91 | USD 2,968,650 | SEC 申报 ↗ |
| 2020-11-10 | SACHS BRUCE I | 买入 (P) | Common Stock | 15,000 | USD 217.36 | USD 3,260,465 | SEC 申报 ↗ |
Form 4 申报证据
190 transaction lines in the latest 365-day window; 1,980 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | van Grunsven Jasper | 奖励／授予 (A) | Common Stock | 8,682 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-28 | Ambrose Kristen | 奖励／授予 (A) | Common Stock | 5,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-27 | SACHS BRUCE I | 赠与 (G) | Common Stock | 6,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | van Grunsven Jasper | 奖励／授予 (A) | Common Stock | 8,682 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-28 | Ambrose Kristen | 奖励／授予 (A) | Common Stock | 5,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-27 | SACHS BRUCE I | 赠与 (G) | Common Stock | 6,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-21 | Tatsis Ourania | 奖励／授予 (A) | Common Stock | 8,251 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-21 | Sachdev Amit | 奖励／授予 (A) | Common Stock | 8,251 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-02 | Tatsis Ourania | 卖出 (S) | Common Stock | 1,500 | USD 524.99 | USD 787,485 | SEC 申报 ↗ |
| 2026-07-02 | McKechnie Duncan | 卖出 (S) | Common Stock | 1,541 | USD 519.00 | USD 799,779 | SEC 申报 ↗ |
| 2026-07-01 | Liu Joy | 卖出 (S) | Common Stock | 828 | USD 502.71 | USD 416,244 | SEC 申报 ↗ |
| 2026-06-26 | Bozic Carmen | 卖出 (S) | Common Stock | 596 | USD 482.50 | USD 287,570 | SEC 申报 ↗ |
| 2026-06-18 | Bozic Carmen | 卖出 (S) | Common Stock | 1,020 | USD 462.17 | USD 471,413 | SEC 申报 ↗ |
| 2026-06-15 | Bozic Carmen | 卖出 (S) | Common Stock | 4,062 | USD 450.00 | USD 1,827,900 | SEC 申报 ↗ |
| 2026-06-05 | Bozic Carmen | 卖出 (S) | Common Stock | 1,745 | USD 450.00 | USD 785,250 | SEC 申报 ↗ |
| 2026-06-01 | Liu Joy | 卖出 (S) | Common Stock | 828 | USD 439.91 | USD 364,245 | SEC 申报 ↗ |
| 2026-05-29 | Bozic Carmen | 卖出 (S) | Common Stock | 1,974 | USD 450.00 | USD 888,300 | SEC 申报 ↗ |
| 2026-05-15 | Bunnage Mark E. | 卖出 (S) | Common Stock | 33 | USD 453.45 | USD 14,964 | SEC 申报 ↗ |
| 2026-05-15 | Bozic Carmen | 卖出 (S) | Common Stock | 1,354 | USD 453.45 | USD 613,971 | SEC 申报 ↗ |
| 2026-05-12 | Bozic Carmen | 卖出 (S) | Common Stock | 6,988 | USD 450.00 | USD 3,144,600 | SEC 申报 ↗ |
| 2026-05-04 | Bhatia Sangeeta N. | 卖出 (S) | Common Stock | 318 | USD 423.73 | USD 134,746 | SEC 申报 ↗ |
| 2026-05-01 | Upadhyay Suketu | D (D) | Common Stock | 796 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-01 | Thornberry Nancy | D (D) | Common Stock | 398 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-01 | Thornberry Nancy | 奖励／授予 (A) | Common Stock | 472 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-01 | Schneider Jennifer | D (D) | Common Stock | 796 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-01 | Schneider Jennifer | 奖励／授予 (A) | Common Stock | 472 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-01 | MCKENZIE DIANA | D (D) | Common Stock | 796 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-01 | MCKENZIE DIANA | 奖励／授予 (A) | Common Stock | 943 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-01 | Liu Joy | 卖出 (S) | Common Stock | 1,104 | USD 425.02 | USD 469,222 | SEC 申报 ↗ |
| 2026-05-01 | Garber Alan M | 奖励／授予 (A) | Common Stock | 472 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-01 | Bhatia Sangeeta N. | 奖励／授予 (A) | Common Stock | 943 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-01 | Liu Joy | 卖出 (S) | Common Stock | 978 | USD 449.17 | USD 439,288 | SEC 申报 ↗ |
| 2026-03-27 | Bozic Carmen | 卖出 (S) | Common Stock | 2,329 | USD 450.95 | USD 1,050,263 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | VRTX |
| CIK | 0000875320 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 1,980 transaction lines from 2020-01-02 to 2026-09-08 10 P purchase lines · 1,268 S sale lines · 702 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.